PATENT CLAIM ANALYSIS

Application Number: 15874544
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: 50-95 wt. % of a granulate; 5-50 wt. % of lactose; and 0-30 wt. % of other tablet excipients;   wherein the granulate contains:  a. 2-15 wt. % of cannabidiol; b. 2-30 wt. % of sucrose fatty acid mono-ester; c. 30-96 wt. % of lactose; and d. 0-25 wt. % of other granulate excipients.   The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.

Claim (Index 14):
The method according to  claim 12 , wherein the anxiety disorder is selected from phobic disorder, generalized anxiety disorder, and/or post-traumatic stress disorder.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 86.0
- Lexical Diversity: 2.08571
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15032905', '15032925', '15223783', '12441342', '16094802']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7497699808200942
- 35 USC 102 Novelty (BERT): 0.5587766151596438
- Combined Prediction Score: 0.7306706442540492
- Mean Citation Score: 325.85981400000014
- Max Citation Score: 495.0519
- Similarity Product: 283.55937464658024

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test